PBM revenueFY2026$263.4K
- FY YoY
- +175.0%
PBM revenue was $263.4K for fiscal 2026 (ended Mar 31, 2026), up 175.0% from fiscal 2025. It rose in each of the last 3 fiscal years.
Psyence Biomedical Ltd. (PBM) financials
For fiscal 2026 (ended Mar 31, 2026), Psyence Biomedical Ltd. reported $263.4K of revenue and -$6.94M of net income.
- Revenue, FY2026
- $263.4K
- Revenue growth, YoY
- +175.0%
- Net income, FY2026
- -$6.94M
- Net margin
- -2633.7%
- Free cash flow, FY2026
- -$8.14M
- EPS, diluted, FY2026
- -$12.56
- Cash
- $7.44M
- P/S
- 60.95
- Market cap
- $16.1M
FY2023FY2026
FY2023FY2026
FY2024FY2026
PBM revenue and earnings growth
PBM net incomeFY2026-$6.94M
PBM net income was -$6.94M for fiscal 2026 (ended Mar 31, 2026), compared with $1.01M in fiscal 2025.
PBM EPSFY2026-$12.56
PBM diluted EPS was -$12.56 for fiscal 2026 (ended Mar 31, 2026).
PBM free cash flowFY2026-$8.14M
PBM free cash flow was -$8.14M for fiscal 2026 (ended Mar 31, 2026), compared with -$3.74M in fiscal 2025.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Revenue | $263.4K | $95.8K | $2.1K | $1.6K |
| Research and development | $1.47M | $342.2K | $954.6K | $1.61M |
| Selling, general and admin | $892.3K | $1.21M | $557.9K | $366.4K |
| Interest expense | $9.5K | $9.3K | $52.9K | - |
| Pre-tax income | -$6.23M | -$3.66M | -$2.75M | -$3.23M |
| Net income | -$6.94M | $1.01M | -$51.16M | -$3.21M |
| EPS, basic | -$12.56 | $32.76 | -$29214.06 | -$2462.88 |
| EPS, diluted | -$12.56 | $32.76 | -$29214.06 | -$2462.88 |
| Diluted shares | 552,282 | 30,887 | 1,744 | 1,338.4 |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Cash and equivalents | $7.44M | $6.14M | $733.2K | $1.33M |
| Current assets | $9.11M | $6.56M | $1.13M | $1.59M |
| Total assets | $17.57M | $7.32M | $1.13M | $1.59M |
| Total debt | - | - | $10.45M | - |
| Total liabilities | $623.2K | $594.4K | $12.10M | $1.79M |
| Shareholders' equity | $16.94M | $6.72M | -$10.97M | -$200.4K |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Operating cash flow | -$8.14M | -$3.73M | -$2.95M | -$1.59M |
| Capital expenditures | $229 | $9.9K | $5.7K | - |
| Free cash flow | -$8.14M | -$3.74M | -$2.95M | - |
| Investing cash flow | -$4.51M | -$16.2K | -$5.7K | - |
| Financing cash flow | $13.96M | $9.15M | $2.35M | $1.17M |
| Stock-based compensation | $155.3K | - | $317.9K | $221.3K |
Key ratios
Source: XBRL data Psyence Biomedical Ltd. files with the SEC, latest filing dated Jun 22, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures and share counts are restated for stock splits the filings show: 4-for-25, first reported Jun 22, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
PBM peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PBM | $263.4K | +175.0% | -$6.94M | -2633.7% | $16.1M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
PBM FAQ
8 questionsWhat is PBM revenue?
Psyence Biomedical Ltd. (PBM) reported $263.4K of revenue for fiscal 2026 (ended Mar 31, 2026). That is up 175.0% from the year before.Is PBM profitable?
No. Psyence Biomedical Ltd. reported a net loss of $6.94M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does PBM have?
Psyence Biomedical Ltd. reported $7.44M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is PBM revenue growing?
Psyence Biomedical Ltd.'s revenue changed +175.0% in fiscal 2026, to $263.4K.What is PBM free cash flow?
Psyence Biomedical Ltd. generated -$8.14M of free cash flow for fiscal 2026 (ended Mar 31, 2026), which is operating cash flow of -$8.14M less capital expenditures.What is PBM earnings per share?
Diluted earnings per share were -$12.56 for fiscal 2026 (ended Mar 31, 2026), from SEC filings, restated for any stock split those filings show.When did PBM last report financial results?
The latest statements here come from Psyence Biomedical Ltd.'s 20-F filed on Jun 22, 2026, covering the period ended Mar 31, 2026.Where does this PBM financial data come from?
Quantisnow builds these statements from the structured XBRL data Psyence Biomedical Ltd. files with the SEC. It is provided for information only and is not investment advice.